FLNA antibody
- Known as:
- FLNA (anti-)
- Catalog number:
- orb95924
- Product Quantity:
- EUR
- Category:
- -
- Supplier:
- Biorbyt biorb
- Gene target:
- FLNA antibody
Related genes to: FLNA antibody
- Gene:
- FLNA NIH gene
- Name:
- filamin A
- Previous symbol:
- FLN1, FLN, OPD2, OPD1
- Synonyms:
- ABP-280
- Chromosome:
- Xq28
- Locus Type:
- gene with protein product
- Date approved:
- 1993-03-18
- Date modifiied:
- 2019-04-23
Related products to: FLNA antibody
Related articles to: FLNA antibody
- Hypertension is a major risk factor for cardiovascular diseases. RNA N6-methyladenosine (mA) modification is closely linked to hypertension pathogenesis, but key mA-related factors that regulate blood pressure remain unclear. This study aims to identify these regulators and evaluate their therapeutic potential. - Source: PubMed
Publication date: 2026/08/25
Chen ZhenzhenZhang HaizengYang QiaoxiFan LuyunDong XilanLing QianhuiGuo XinruYue FengkaiCui JiaruiTang YanGeng BinCai Jun - To clarify the role of filamin A (FLNA) in promoting diabetic retinopathy (DR) progression and explore its underlying mechanism modulating M1 macrophage inflammation and adenosine 5'-monophosphate activated protein kinase (AMPK) phosphorylation, as well as its potential as a diagnostic biomarker and therapeutic target. - Source: PubMed
Publication date: 2026/09/18
Li Chun-HuaFeng Mao-FeiZhang XueYu Lei - Congenital short bowel syndrome (CSBS) is a rare intestinal disorder characterized by inborn shortening of the bowel with mainly mutations in Coxsackie and Adenovirus receptor-like membrane protein (CLMP) and Filamin A (FLNA) genes. Clinical features are not well described; therefore, we aim to improve patient care by evaluating diagnostic approaches and identifying prognostic factors through the analysis of published cases. - Source: PubMed
Publication date: 2026/08/13
Remund BarblinSchibli SusanneSokollik Christiane - PurposeTo elucidate the dynamic molecular evolution and immune heterogeneity in diabetic retinopathy (DR) and identify diagnostic biomarkers.MethodsMulti-omics integrative analysis was performed on peripheral blood transcriptomic data from diabetic patients with and without DR. Techniques included differential expression analysis, immune infiltration profiling, unsupervised clustering, and LASSO regression for biomarker selection. Findings were validated in an independent high-glucose-treated endothelial cell model.ResultsDR progression exhibits staged molecular evolution from diabetes (immune suppression) to early DR (cell cycle inhibition, immune burst) and advanced DR (metabolic stress, persistent immune dysregulation). Six co-downregulated immune modules indicated systemic immune suppression. Patients were classified into three immune subtypes: vascular-inflammatory, metabolic disorder, and oxidative stress-tissue remodeling. A diagnostic model based on IK, PLBD2, FLNA, H6PD, and ZMAT2 achieved an AUC of 0.876 for distinguishing DR from diabetes alone.ConclusionThis study delineates the dynamic molecular landscape and immune heterogeneity of DR, providing a potential multi-gene diagnostic signature and a framework for patient stratification, which may facilitate early detection and personalized management. - Source: PubMed
Publication date: 2026/08/04
Zhang JiweiZhang LinglinYu ZhihongYang GaojieYu Liling - FLNA encodes filamin A, a cytoskeletal actin-binding protein with critical roles in neuronal migration, mechano-transduction, and organ morphogenesis. Pathogenic FLNA variants are classically associated with periventricular nodular heterotopia (PVNH), epilepsy, and multisystem manifestations, although interpretation of missense variants remains challenging because of marked variable expressivity and limited functional evidence. - Source: PubMed
Publication date: 2026/08/03
Bombaci AlessandroMicaglio EmanueleBenedetti SaraStufano GianlucaCutillo GianniDoddato GabriellaRossi Sergio SoerenMazzeo SalvatorePappone CarloFilippi MassimoSalsone Maria